Neumora Therapeutics (NMRA) Other Non Operating Income (2022 - 2026)
Neumora Therapeutics' (NMRA) quarterly Other Non Operating Income came in at $59000.0 in Q1 2026, up 336.0% year-on-year from $13532.1 in Q1 2025, and down 98.79% quarter-over-quarter from $4.9 million in Q4 2025.
Neumora Therapeutics (NMRA) Other Non Operating Income (2022 - 2026) Analysis & Trends
Neumora Therapeutics' Other Non Operating Income history runs 5 years deep, the most recent figure standing at $59000.0 for Q1 2026.
- On a quarterly basis, Other Non Operating Income rose 336.0% year-over-year to $59000.0 in Q1 2026; TTM through Mar 2026 was $4.5 million, a 5000.0% increase from a year earlier, with the FY2025 full-year figure at $4.4 million, up 5708.97% from the prior year.
- Other Non Operating Income retreated to $59000.0 in Q1 2026 per NMRA's latest filing, from $4.9 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $4.9 million in Q4 2025 and bottomed at -$480000.0 in Q2 2025.
- The 5-year median for Other Non Operating Income is -$24000.0 (2024), against an average of $288333.3.
- Across the five-year window, Other Non Operating Income slumped 5600.0% in 2024 and surged 32386.67% in 2025, its largest moves.
- Year by year, Other Non Operating Income stood at $287000.0 in 2022, then plunged by 136.24% to -$104000.0 in 2023, then soared by 114.42% to $15000.0 in 2024, then jumped by 32386.67% to $4.9 million in 2025, then plunged by 98.79% to $59000.0 in 2026.
- Per Business Quant, the three latest NMRA Other Non Operating Income figures stand at $59000.0 (Q1 2026), $4.9 million (Q4 2025), and $7000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Neumora Therapeutics | 270.71 Mn | 270.71 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 59,000.00 |
| Dec 31, 2025 | 4.87 Mn |
| Sep 30, 2025 | 7,000.00 |
| Jun 30, 2025 | -480,000.00 |
| Mar 31, 2025 | -25,000.00 |
| Dec 31, 2024 | 15,000.00 |
| Sep 30, 2024 | -57,000.00 |
| Jun 30, 2024 | -24,000.00 |
| Mar 31, 2024 | -12,000.00 |
| Dec 31, 2023 | -104,000.00 |
| Sep 30, 2023 | -1,000.00 |
| Jun 30, 2023 | -39,000.00 |
| Mar 31, 2023 | -26,000.00 |
| Dec 31, 2022 | 287,000.00 |
| Sep 30, 2022 | -148,000.00 |